{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:52:47Z","timestamp":1794736367734,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The pivotal ZUMA-2 trial evaluated the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed\/refractory (R\/R) mantle cell lymphoma (MCL), and ultimately led to the approval of brexu-cel for R\/R MCL. Here we report a retrospective analysis of data and samples from ZUMA-2, analyzed by exposure to class of Bruton tyrosine kinase inhibitor (BTKi; first-generation ibrutinib vs second-generation acalabrutinib) in a treatment line before brexu-cel. We found that the ibrutinib-exposed group had significantly greater duration of progression-free survival, greater CAR T-cell expansion, and more CAR T-cell\u2013related toxicity than the acalabrutinib-exposed group. Brexu-cel products from the ibrutinib-treated patients had increased frequencies of T helper 17 cells and transcriptional signatures associated with cytotoxic function. Seven days after infusion, peripheral blood CAR T cells from ibrutinib-exposed patients showed more pronounced effector memory differentiation, which independently correlated to clinical response to brexu-cel. In contrast, brexu-cel products from acalabrutinib-treated patients were enriched for central memory phenotypes and less effector differentiated at day 7 after infusion. Our findings revealed CAR T-cell phenotypic associations with previous BTKi use, and highlight BTKi exposure as a potentially important clinical variable in ZUMA-2 worthy of further study in efforts to improve CAR T-cell therapies. This trial was registered at www.ClinicalTrials.gov as NCT02601313.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018137","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:31:58Z","timestamp":1770827518000},"page":"1023-1034","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5535-084X","authenticated-orcid":false,"given":"Eli P.","family":"Darnell","sequence":"first","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M. E.","family":"Gallagher","sequence":"additional","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kanska","sequence":"additional","affiliation":[{"name":"4Kite, A Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Balderrama-Gutierrez","sequence":"additional","affiliation":[{"name":"4Kite, A Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha R.","family":"Berger","sequence":"additional","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0908-1508","authenticated-orcid":false,"given":"Justin","family":"Budka","sequence":"additional","affiliation":[{"name":"4Kite, A Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Bozym","sequence":"additional","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarinee","family":"Huang","sequence":"additional","affiliation":[{"name":"4Kite, A Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhine","family":"Shen","sequence":"additional","affiliation":[{"name":"4Kite, A Gilead Company, Santa Monica, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[{"name":"1Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA"},{"name":"2Cellular Immunotherapy Program, Mass General Hospital Cancer Center, Boston, MA"},{"name":"3Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"10121","key":"2026022411384597800_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"2026022411384597800_bib2","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"10441","key":"2026022411384597800_bib3","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","article-title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"issue":"14","key":"2026022411384597800_bib4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2026022411384597800_bib5","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026022411384597800_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026022411384597800_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1146\/annurev.immunol.22.012703.104743","article-title":"Tec family kinases in T lymphocyte development and function","volume":"23","author":"Berg","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"11","key":"2026022411384597800_bib8","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","article-title":"The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma","volume":"22","author":"Ruella","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026022411384597800_bib9","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"issue":"9","key":"2026022411384597800_bib10","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"2026022411384597800_bib11","doi-asserted-by":"crossref","first-page":"106520","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk Res"},{"issue":"21","key":"2026022411384597800_bib12","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026022411384597800_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-021-03136-2","article-title":"Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence","volume":"19","author":"Davis","year":"2021","journal-title":"J Transl Med"},{"issue":"8","key":"2026022411384597800_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"issue":"16","key":"2026022411384597800_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026022411384597800_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"26","key":"2026022411384597800_bib17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2026022411384597800_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fimmu.2020.00166","article-title":"Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-color EuroFlow immune monitoring tube","volume":"11","author":"Botafogo","year":"2020","journal-title":"Front Immunol"},{"issue":"19","key":"2026022411384597800_bib19","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026022411384597800_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"issue":"13","key":"2026022411384597800_bib21","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2013-03-488411","article-title":"Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans","volume":"122","author":"Westera","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2026022411384597800_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/imm.12074","article-title":"T-cell memory differentiation: insights from transcriptional signatures and epigenetics","volume":"139","author":"Youngblood","year":"2013","journal-title":"Immunology"},{"issue":"10","key":"2026022411384597800_bib23","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.4049\/jimmunol.175.10.6489","article-title":"Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27","volume":"175","author":"Fritsch","year":"2005","journal-title":"J Immunol"},{"key":"2026022411384597800_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2018.11.015","article-title":"A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders","volume":"105","author":"Kamali","year":"2019","journal-title":"Mol Immunol"},{"issue":"3","key":"2026022411384597800_bib25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/ijms19030730","article-title":"The balance of Th17 versus Treg cells in autoimmunity","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2026022411384597800_bib26","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026022411384597800_bib27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026022411384597800_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","article-title":"Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7)","volume":"5","author":"Filosto","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026022411384597800_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026022411384597800_bib30","doi-asserted-by":"crossref","first-page":"637186","DOI":"10.3389\/fonc.2021.637186","article-title":"TH2\/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia","volume":"11","author":"Puzzolo","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"2026022411384597800_bib31","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026022411384597800_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00262-016-1797-6","article-title":"Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic","volume":"65","author":"Majchrzak","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2026022411384597800_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3324\/haematol.2011.047316","article-title":"Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance","volume":"97","author":"Jain","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"2026022411384597800_bib34","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1023\/2502890\/blooda_adv-2025-018137-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1023\/2502890\/blooda_adv-2025-018137-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:57Z","timestamp":1771951137000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1023\/557002\/Ibrutinib-exposure-correlates-with-improved"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018137","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,11]]}}}